ESPE Abstracts (2019) 92 RFC3.6

ESPE2019 Rapid Free Communications Multi-system Endocrine Disorders (6 abstracts)

Prevalence of Endocrine Complications in Duchenne Muscular Dystrophy

Primož Kotnik 1,2 , Sončka Jazbinšek 1 , Tanja Golli 3 & Damjan Osredkar 3

1Department of Endocrinology, Diabetes and Metabolism, University Children's Hospital, University Medical Centre Ljubljana, Ljubljana, Slovenia. 2Department of Paediatrics, Medical Faculty, University of Ljubljana, Ljubljana, Slovenia. 3Department of Child, Adolescent and Developmental Neurology, University Children's Hospital, University Medical Centre Ljubljana, Ljubljana, Slovenia

Background: Duchenne muscular dystrophy (DMD) is caused by mutations in the dystrophin gene and results in a progressive muscular damage and degeneration. Endocrine complications result from decreased energy expenditure, immobility and glucocorticoid (GC) treatment. Due to the multidisciplinary management and emerging genetic and molecular therapies longer survival is expected and there is an increasing emphasis on the quality of life in DMD. Aim of the study was to determine prevalence of selected endocrine complications in a national cohort of boys with DMD treated or not with GC.

Methods: 29 boys with DMD (age (mean+/-SD) 11.5+/-5.4 years) were studied at annual multidisciplinary visit. Levels of IGF-1, IGF-BP3, TSH, free T4, glucose, insulin and vitamin D3 were determined in the morning following an overnight fast. Bone mineral density and body composition were determined by DEXA. Data were expressed as mean+/-SD, groups were compared by T-test, correlations were made by Pearson's coefficient. P-values < 0.05 were considered statistically significant.

Results: 13/29 received GC (deflacort) for 3.6+/-3.1 year (starting at 6.9+/-.8 years). 7/29 were short stature (2 in GC group), 1/29 (0 in GC group) was underweight and 6/29 (3 in GC group) were overweight. HOMA-IR was increased in 8/29 (5 in GC group), none had impaired glucose tolerance or diabetes. No cases of acute adrenal insufficiency were reported. Lumbar spine-BMD was decreased in 8/29 (3 in GC group), 24/29 received vitamin D3 supplements and one subject needed antiresorptive therapy.

There were no differences in the mean values of selected parameters between those receiving or not-receiving GC. Glucocorticoid treatment duration however correlated positively with BMI-SDS and % fat mass (r=0,722, P= and r=0.84, P=.018 respectively) and negatively with % lean mass (-.88, P=.004).

Conclusions: Short stature, under and overweight, insulin resistance and decreased BMD are common however not obligatory endocrine complications in DMD. Although there were no differences in studied parameters between those receiving and not-receiving GC, there was a positive correlation between GC treatment duration and BMI-SDS and increased fat mass confirming GC as a risk factor for possible metabolic complications in DMD.

Volume 92

58th Annual ESPE

Vienna, Austria
19 Sep 2019 - 21 Sep 2019

European Society for Paediatric Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.